The reclassification reduces regulatory risk and shortens the timeline to a potential November 10, 2026 PDUFA/GDUFA decision. Traders should monitor for FDA action around that date and any subsequent commercial launch updates for NRX-100.
Price Chart
Executive Summary
NRx Pharmaceuticals announced that the FDA reclassified its ANDA amendment for preservative-free ketamine (NRX-100) from a Major Amendment to a Minor Amendment, pulling the GDUFA goal date forward to November 10, 2026. This regulatory de-escalation signals a lower review burden and accelerates the timeline toward potential approval of a drug-shortage product, a modest but positive catalyst for a clinical-stage biopharma with a $147M market cap.
Key Facts
- FDA reclassified NRx's ANDA amendment from Major to Minor Amendment.
- GDUFA goal date revised to November 10, 2026.
- FDA cited the reclassified amendment will not require a substantial expenditure of resources.
- Product is preservative-free ketamine (NRX-100), designated a drug shortage product.
- NRX-100 has Fast Track Designation for suicidal ideation in depression.
Financial Impact
No financial figures provided; regulatory milestone accelerates potential market entry for a drug-shortage product.
Risk Factors
- FDA may still issue a Complete Response Letter (CRL) at the goal date.
- Company remains clinical-stage with no approved products; cash runway and commercial execution are unproven.
- Historical calibration shows mixed T+20 outcomes for prior bullish reports on NRXP, with some large drawdowns.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-030492 |
| Exhibit: ex_1016862.htm | 0001437749-26-030492 |
| Document: 0001437749-26-030492-index-headers.html | 0001437749-26-030492 |
| Document: 0001437749-26-030492-index.html | 0001437749-26-030492 |
| Document: 0001437749-26-030492.txt | 0001437749-26-030492 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 8-K | $3.35 $3.16 | ▼ −5.67% | ▼ −8.24% | $2.90 (−13.28%) |
Sep 14, 2026 18d ago | 8-K | $3.49 $3.29 | ▼ −5.73% | ▼ −5.84% | $2.90 (−16.76%) |
Aug 17, 2026 6w ago | 8-K | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 17, 2026 6w ago | Press Release | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 7, 2026 8w ago | 8-K | $3.58 $3.27 | ▼ −8.66% | ▼ −9.06% | $2.90 (−18.85%) |
Jul 22, 2026 10w ago | 8-K | $4.48 $3.23 | ▼ −27.90% | ▼ −25.50% | $2.90 (−35.16%) |
Jun 22, 2026 14w ago | Press Release | $3.90 $3.73 | ▼ −4.36% | ▼ −2.29% | $2.90 (−25.51%) |
Jun 5, 2026 17w ago | Press Release | $4.14 $3.84 | ▼ −7.25% | ▼ −7.82% | $2.90 (−29.83%) |
Jun 4, 2026 17w ago | Press Release | $4.14 $3.84 | ▲ +7.25% | ▲ +7.82% | $2.90 (+29.83%) |
Jun 3, 2026 17w ago | Press Release | $4.05 $3.76 | ▲ +7.16% | ▲ +3.34% | $2.90 (+28.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access